PMID- 33860045
OWN - NLM
STAT- MEDLINE
DCOM- 20210525
LR  - 20240226
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2021
DP  - 2021
TI  - Human Schlafen 5 Inhibits Proliferation and Promotes Apoptosis in Lung 
      Adenocarcinoma via the PTEN/PI3K/AKT/mTOR Pathway.
PG  - 6628682
LID - 10.1155/2021/6628682 [doi]
LID - 6628682
AB  - BACKGROUND: Human Schlafen 5 (SLFN5) is reported to inhibit or promote the 
      proliferation of several specific types of cancer cells by our lab and other 
      researchers. We are curious about its implications in lung adenocarcinoma (LUAC), 
      a malignant tumor with a high incidence rate and high mortality. METHOD: 
      Lentiviral stable transfections of SLFN5-specific shRNA for knockdown and SLFN5 
      full-length coding sequence for overexpression were performed in LUAC cell for 
      proliferation analysis in vitro and in vivo in nude mice. Clinical LUAC samples 
      were collected for immunohistochemical analysis of SLFN5 protein levels. RESULTS: 
      We found that knockdown of endogenous SLFN5 upregulates cancer cell proliferation 
      while inhibiting apoptosis. Besides, SLFN5 inhibition on proliferation was also 
      observed in a nude mouse xenograft model. In contrast, overexpression of 
      exogenous SLFN5 inhibited cell proliferation in vitro and in vivo and promoted 
      apoptosis. As to the signaling pathway, we found phosphatase and tensin homolog 
      on chromosome 10 (PTEN) was positively regulated by SLFN5, while its downstream 
      signaling pathway AKT/mammalian target of rapamycin (mTOR) was inhibited. 
      Moreover, compared with adjacent normal tissues, SLFN5 protein levels were 
      markedly decreased in lung adenocarcinoma tissues. In conclusion, these suggest 
      that human SLFN5 plays inhibitory roles in LUAC progression through the 
      PTEN/PI3K/AKT/mTOR pathway, providing a potential target for developing drugs for 
      lung cancer therapy in the future.
CI  - Copyright (c) 2021 Xuefeng Gu et al.
FAU - Gu, Xuefeng
AU  - Gu X
AD  - Shanghai University of Medicine & Health Science Affiliated Zhoupu Hospital, 
      Shanghai, China.
AD  - Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine & 
      Health Sciences, Shanghai, China.
FAU - Zhou, Li
AU  - Zhou L
AD  - Shanghai University of Medicine & Health Science Affiliated Zhoupu Hospital, 
      Shanghai, China.
FAU - Chen, Lei
AU  - Chen L
AD  - Shanghai University of Medicine & Health Science Affiliated Zhoupu Hospital, 
      Shanghai, China.
AD  - Shanghai University of Traditional Chinese Medicine, Shanghai, China.
FAU - Pan, Huiqing
AU  - Pan H
AD  - Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine & 
      Health Sciences, Shanghai, China.
FAU - Zhao, Rui
AU  - Zhao R
AD  - Shanghai University of Medicine & Health Science Affiliated Zhoupu Hospital, 
      Shanghai, China.
AD  - Shanghai University of Traditional Chinese Medicine, Shanghai, China.
FAU - Guang, Weiwei
AU  - Guang W
AD  - Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine & 
      Health Sciences, Shanghai, China.
FAU - Wan, Guoqing
AU  - Wan G
AD  - Shanghai University of Medicine & Health Science Affiliated Zhoupu Hospital, 
      Shanghai, China.
AD  - Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine & 
      Health Sciences, Shanghai, China.
FAU - Zhang, Peng
AU  - Zhang P
AD  - Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine & 
      Health Sciences, Shanghai, China.
FAU - Liu, Dingsheng
AU  - Liu D
AD  - Shanghai University of Medicine & Health Science Affiliated Zhoupu Hospital, 
      Shanghai, China.
FAU - Deng, Li-Li
AU  - Deng LL
AD  - Department of Oncology, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, Heilongjiang, China.
FAU - Zhao, Weiming
AU  - Zhao W
AD  - Qiqihar Medical University, Qiqihar, Heilongjiang, China.
FAU - Lu, Changlian
AU  - Lu C
AUID- ORCID: 0000-0002-0812-9162
AD  - Shanghai University of Medicine & Health Science Affiliated Zhoupu Hospital, 
      Shanghai, China.
AD  - Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine & 
      Health Sciences, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20210323
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (SLFN5 protein, human)
RN  - EC 2.7.11.1 (Glycogen Synthase Kinase 3 beta)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
SB  - IM
RIN - Biomed Res Int. 2024 Jan 9;2024:9767180. PMID: 38230125
MH  - A549 Cells
MH  - Adenocarcinoma of Lung/genetics/metabolism/*pathology
MH  - Animals
MH  - *Apoptosis
MH  - Cell Cycle Proteins/*metabolism
MH  - Cell Proliferation
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Knockdown Techniques
MH  - Glycogen Synthase Kinase 3 beta/metabolism
MH  - Humans
MH  - Lung Neoplasms/genetics/metabolism/*pathology
MH  - Mice, Nude
MH  - PTEN Phosphohydrolase/*metabolism
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - Phosphorylation
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/*metabolism
MH  - Transcription, Genetic
MH  - Mice
PMC - PMC8009730
COIS- The authors have declared that no competing interest exists.
EDAT- 2021/04/17 06:00
MHDA- 2021/05/26 06:00
PMCR- 2021/03/23
CRDT- 2021/04/16 06:40
PHST- 2020/12/08 00:00 [received]
PHST- 2021/01/06 00:00 [revised]
PHST- 2021/01/21 00:00 [accepted]
PHST- 2021/04/16 06:40 [entrez]
PHST- 2021/04/17 06:00 [pubmed]
PHST- 2021/05/26 06:00 [medline]
PHST- 2021/03/23 00:00 [pmc-release]
AID - 10.1155/2021/6628682 [doi]
PST - epublish
SO  - Biomed Res Int. 2021 Mar 23;2021:6628682. doi: 10.1155/2021/6628682. eCollection 
      2021.